FDA Disclaimer General Disclaimer: These statements have not been evaluated by the Food and Drug Administration
Published work characterizes SLU-PP-332 as a chemical tool with in vivo activity suitable for modeling exercise-responsive transcriptional programs in preclinical systems
Historically, the agency tends to go in accordance with its advisory committee
This faster recovery may help athletes improve their performance rapidly by increasing training frequency and intensity [9]
longum BB 536 demonstrated to modulate the expression of TJPs, with the increase of zonulin-1 and 2, occluding and claudin-1, and to prevent inflammatory damage, in an in vitro model of intestinal barrier developed using Caco-2 cell monolayer [14]
Oral administration allows for easy daily use without the discomfort, complexity or potential side effects associated with injections